https://www.selleckchem.com/pr....oducts/Pomalidomide(
High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Of 22463 patients in ESME-MBC, 12999 women had BMI data available at MBC diagnosis. Median BMI was 24.9kg/m